需要哺乳支持的母亲可能从产后早期催乳素治疗中获益：单中心经验。
Mothers in Need of Lactation Support May Benefit from Early Postnatal Galactagogue Administration: Experience from a Single Center.
机构信息
Neonatal Department, Medical School, National and Kapodistrian University of Athens, Aretaieio Hospital, 11526 Athens, Greece.
Second Department of Pathology, Medical School, National and Kapodistrian University of Athens, University General Hospital Attikon, 12462 Athens, Greece.
出版信息
Nutrients. 2021 Dec 29;14(1):140. doi: 10.3390/nu14010140.
BACKGROUND
Galactagogues are substances that promote lactation, although data on their effects on humans remain limited. We investigated the efficacy of Silitidil to increase milk supply and duration of breastfeeding of a specific subgroup of mothers in need of lactation support.
METHODS
161 mothers from November 2018 until January 2021 were the study subjects in this retrospective study; during their hospitalization, due to neonatal or maternal factors that inhibited lactation, they were prescribed galactagogues. Mothers were surveyed by telephone interview via a 13-item questionnaire.
RESULTS
73.91%, were primigravidas, 78.26% gave birth by cesarean section (CS) and 72.05% continued to take galactagogues after hospital discharge. Of the neonates, 24.22% were preterm ≤37 weeks of gestation, and 55.9% had birth weight (BW) between 2500 and 3500 g. With respect to breastfeeding rates, 100% were breastfed during their first week, 98.8% breastfed during the first month, 87% during the first 4 months, dropping to 56.5% at 6 months, 41% at 1 year and 19.3% over 1 year of age.
CONCLUSIONS
This study demonstrates that administration of a galactagogue containing Silitidil (Piulatte-Humana) improves breastfeeding rates at from 1 until 12 months of life in mothers with low milk supply during their hospital stay. Further studies are needed to generate evidence-based strategies to improve breastfeeding outcomes.
背景
催奶剂是促进泌乳的物质，但其对人类的作用数据仍有限。我们研究了西利替利（Silitidil）增加特定有哺乳支持需求的低奶量母亲泌乳量和延长母乳喂养时间的效果。
方法
本回顾性研究的研究对象为 2018 年 11 月至 2021 年 1 月期间的 161 名母亲；由于新生儿或母亲因素抑制泌乳，她们在住院期间被开具催奶剂。通过 13 项问卷的电话访谈对母亲进行调查。
结果
73.91%为初产妇，78.26%行剖宫产（CS）分娩，72.05%在出院后继续服用催奶剂。新生儿中，24.22%为胎龄≤37 周的早产儿，55.9%的出生体重（BW）在 2500 至 3500 克之间。母乳喂养率方面，100%在第一周母乳喂养，98.8%在第一个月母乳喂养，87%在头 4 个月母乳喂养，6 个月时下降至 56.5%，1 岁时下降至 41%，1 岁以上时下降至 19.3%。
结论
本研究表明，在住院期间泌乳量低的母亲中使用含有西利替利（Piulatte-Humana）的催奶剂可提高从 1 至 12 个月龄的母乳喂养率。需要进一步研究以制定基于证据的策略来改善母乳喂养结局。
Zotero 插件